Yuanmei Li1,2, Qing Gong2, Jiansheng Wang2,*, Yi Zhang2,*
1Department of Endocrinology, Rehabilitation Hospital Affiliated to Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
2Operating Room, Hangzhou Xixi Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
*Corresponding author: Jiansheng Wang, Yi Zhang
Abstract
Objective: To explore the clinical effect of CAF regimen combined with fufangbanmao capsule in the treatment of Thyroid cancer. Methods: From June 2015 to September 2022, our hospital received 118 patients with radical mastectomy after radical surgery and they were divided into the observation group (n=59) and the control group (n=59). The observation group was treated with CAF regimen combined with fufangbanmao capsule, and the control group was treated with CAF alone. The short-term efficacy, NK and T lymphocyte subsets, quality of life and toxicity were compared between the observation groupand the control group. Results: The ORR was 76.27%, and the DCR was 83.05% in the control group; the ORR was 91.53%, and the DCR was 96.61% in the experimental group, the difference was significant (P=0.024, P=0.015). After the intervention, the CD3+, CD4+, CD8+, CD4+/CD8+ and NK indexes in the experimental group were better than those in the control group (P=0.000, P=0.000, P=0.000, P=0.000, P=0.000). In the physiological condition, psychological status, physical condition and sleep condition score, the experimental group was higher than the control group (P=0.012, P=0.014, P=0.009, P=0.013). In the joint pain, bone marrow suppression, arrhythmia, nausea and vomiting, alopecia, thrombocytopenia, leukopenia and anemia drug toxicity, the experimental group was lower than the control group (P>0.05). Conclusion: For Thyroid cancer patients with radical mastectomy, fufangbanmao capsule combined with CAF program could not only improve the short-term clinical efficacy, and improve immunity, but also could reduce drug toxicity and improve quality of life.
References
[1] Chen Wenyou, Liu Jing, Mao Shunbao, et al. The application of docetaxel+epirubicin regimen in neoadjuvant chemotherapy for thyroid cancer [J]. Shanxi Medical Journal, 2018, 42 (07): 745-746.
[2] Liu Chunping, Li Dongxue, Ma Zinc. Nursing of adverse reactions in the treatment of thyroid cancer with paclitaxel combined with epirubicin [J]. Journal of Clinical Rational Drug Use, 2021, 6 (30): 68-69.
[3] Shi Bingshuai, Wang Wensheng, Zhao Aiguo, et al. Short term efficacy of nedaplatin combined with gemcitabine in the treatment of metastatic triple negative thyroid cancer [J]. Journal of Practical Medicine, 2020, 30 (13): 2154-2156.
[4] Qi Jia, Lu Yang, Meng Weiwei. Intravenous care for the treatment of thyroid cancer with epirubicin [J]. Journal of Clinical Rational Drug Use, 2022, 6 (33): 79-80.
[5] Shi Bingshuai, Wang Xiaolei, Dong Jinlong, et al. Clinical and pathological characteristics, treatment methods, and survival after metastasis of triple negative thyroid cancer [J]. Journal of Practical Oncology, 2022-28 (06): 612-614.
[6] Hao Jing, Zhao Pengfei. Retrospective analysis of the efficacy of paclitaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of triple negative thyroid cancer [J]. Chinese Journal of Clinical Pharmacology, 2013, 29 (07): 496-497.
[7] Hao Jing, Zhao Pengfei. A clinical study on the neoadjuvant treatment of locally advanced thyroid cancer with docetaxel, doxorubicin, and cyclophosphamide [J]. Chinese Journal of Clinical Pharmacology, 20121, 10 (04): 303-305.
[8] Que Jingsong. The efficacy of pirarubicin and cyclophosphamide combined with docetaxel in neoadjuvant chemotherapy for thyroid cancer [J]. Chinese Journal of Clinical Physicians (Electronic Edition), 2020, 12 (21): 3870-3874.
[9] Yang Qiumin. Comparison of the efficacy of docetaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of triple negative and non triple negative thyroid cancer [J]. Fundamentals and Clinical Oncology, 2022-27 (04): 297-299.
[10] Hua Baojin, Du Liang, Tang Rongxin. Clinical evidence of compound cantharidin capsules for synergistic treatment of tumors [J]. Chinese Journal of Evidence Based Medicine, 2022-13 (08): 1018-1024.
[11] Han Xiaorong, Yang Jianmin, Luo Yizhong, et al. The preventive effect and mechanism of compound cantharidin capsule on experimental thyroid cancer in rats [J]. Chinese Journal of Thyroid Disease (Electronic Edition), 2022, 7 (05): 329-333.
[12] Jin Zhengnan. Clinical observation on the combination of CAF regimen and compound cantharidin capsules in the treatment of postoperative thyroid cancer [J]. Liaoning Journal of Traditional Chinese Medicine, 2022, 39 (01): 98-99.
[13] Yang Qinhui. Clinical efficacy study of compound cantharidin capsules in the treatment of thyroid cancer [J]. Gansu Science and Technology, 2022, 33 (01): 93-94.
[14] Weng Jianhua, Xu Suzhen, and Hu Meixiao. The application value of epirubicin combined with paclitaxel in the surgical treatment of triple negative thyroid cancer [J]. Hebei Pharmaceutical, 2021, 12 (10): 1468-1470.
[15] Sun Fangyi, Wang Hongfang, Shi Jing, et al. Effects of epirubicin based chemotherapy on cardiac toxicity in patients with thyroid cancer and diabetes [J]. Chinese General Medicine, 2022-20 (15): 1898-1902.
[16] Zhang Xinting. Application and nursing of epirubicin in the treatment of thyroid cancer patients with heart disease [J]. Qilu Journal of Nursing, 2021, 19 (14): 80-81.